

Comparative Analysis of Automated Subcutaneous Micro-Dosing and Synchronized Chronotherapy versus Intramuscular Bolus Administration in Androgen Therapy

Jonathan López Díaz, MD

Division of Biomedical Engineering & Endocrine Research, karē, San Lorenzo, PR

jonathan@karembio.com

Abstract: Traditional testosterone replacement therapy (TRT) relying on bi-weekly intramuscular (IM) injections induces volatile, supraphysiologic hormonal fluctuations, increases the risk of polycythemia, and correlates with low long-term patient compliance. This paper evaluates the physiological and pharmacokinetic differences between large-volume IM boluses and automated, daily-monitored subcutaneous (SC) micro-dosing aligned with natural circadian rhythms. By analyzing the hemodynamic characteristics of the hypodermis, erythropoietin signaling pathways, continuous biomarker co-surveillance metrics (Testosterone and Prostate-Specific Antigen), and operational deployment factors, this study outlines the structural mechanisms governing androgen homeostasis in high-stress and austere environments.

Keywords: Androgen Therapy, Subcutaneous Micro-dosing, Chronotherapy, Erythrocytosis, Proactive Oncological Surveillance, Austere Environment Hemodynamics.

1. Introduction and Clinical Limitations of Intramuscular Therapy

For several decades, large-volume intramuscular (IM) bolus injections of long-acting testosterone esters, such as enanthate and cypionate, have served as the primary therapeutic modality for male hypogonadism. This delivery method introduces specific pharmacokinetic profiles characterized by a distinct peak-and-trough serum concentration curve. Immediately following an intramuscular injection, serum testosterone concentrations elevate into supraphysiologic ranges. This initial concentration peak is followed by a predictable decline, frequently resulting in

sub-therapeutic hormone nadirs prior to the next scheduled administration. These fluctuations correlate with variable symptomatic control and systemic hormonal volatility. Beyond systemic endocrine alterations, the delivery of large-volume, oil-based steroid depots into skeletal muscle tissue involves specific localized risks. Intramuscular delivery carries a documented clinical risk of Pulmonary Oil Microembolism (POME), an acute condition occurring when the viscous oily vehicle accidentally gains direct entry into the local venous vasculature during the injection process. This results in transient respiratory symptoms, including hyperventilation, a coughing reflex, and shortness of breath as the oil micro-globules migrate to the pulmonary capillary bed. Furthermore, the mechanical force required to clear highly viscous hydrophobic solutions through narrow-gauge needles introduces localized mechanical shear stress and tissue trauma. This localized pain and subsequent tissue scarring correlate with low long-term patient compliance data. Clinical tracking indicates that approximately 69% of patients discontinue traditional intramuscular therapy within the first three months of initiation, and up to 95% discontinue the protocol within twelve months.

2. Pathophysiological Mechanics of the Hypodermal Tissue Milieu

The structural and vascular architecture of the subcutaneous hypodermis provides an alternative physiological environment for the absorption of lipophilic compounds compared to skeletal muscle tissue. The variance in absorption kinetics characteristic of intramuscular administration is influenced by the dependency of skeletal muscle tissue on physical movement. Local blood flow and lymphatic drainage within deep muscle groups fluctuate based on physical exertion and active skeletal muscle contractions via extrinsic pumping. Consequently, physical movement or operational exertion triggers variations in the clearance and systemic absorption rates of an intramuscular steroid depot. In contrast, the subcutaneous adipose layer exhibits distinct hemorheological characteristics that isolate the therapeutic depot from the kinetic volatility of physical movement. The hypodermis is less vascularized than skeletal muscle tissue, which limits the baseline rate of direct capillary filtration and restricts rapid systemic clearance of the compound. Furthermore, fluid and macromolecular drainage within the subcutaneous tissue layer is dependent on intrinsic lymphatic pumping, a mechanism

regulated by the autonomous, rhythmic contraction of localized lymphangions equipped with unidirectional valves.

Because this intrinsic subcutaneous lymphatic flow operates independently of external skeletal movement or muscle exertion, the absorption rate of lipophilic testosterone esters remains uniform during physical exertion. This stability is augmented by the molecular characteristics of the tissue layer; the high lipophilicity of testosterone esters reduces spontaneous aqueous hydrolysis within the interstitium, causing the molecules to associate with small local proteins. This protein-associated drainage through the intrinsic lymphatic network modulates central systemic entry and extends the secondary absorption phase, flattening the serum concentration curve into a predictable therapeutic plateau.

3. Chronobiological Synchronization and Circadian Axis Alignment

Endogenous male androgen synthesis is regulated by the central circadian clock network. The pacemaker localized within the suprachiasmatic nucleus (SCN) of the hypothalamus processes ambient photoperiodic stimuli via the retinohypothalamic pathway to align the hypothalamic-pituitary-gonadal (HPG) axis to a 24-hour cycle. The homeostatic orchestration of this axis begins with the activation of this central pacemaker, wherein the SCN translates environmental photoperiodic signals into systemic neuroendocrine signals, modulating the rhythmic release of hypothalamic Gonadotropin-Releasing Hormone (GnRH). This signal drives the pulsatile secretion of Luteinizing Hormone (LH) from the anterior pituitary gland, which flows through the systemic circulation to bind with target receptors on testicular Leydig cells. This molecular engagement triggers intracellular secondary messenger cascades, activating the core transcriptional clock genes *CLOCK* and *BMAL1* to initiate steroidogenesis by upregulating rate-limiting synthetic enzymes within the gonadal tissue. In healthy males, this neuroendocrine cascade results in a distinct circadian baseline. Serum testosterone concentrations reach their physiological peak in the early morning hours, typically around 08:00 AM, a phenomenon coupled with the preservation of normal slow-wave and rapid eye movement (REM) sleep architecture. Following this morning peak, levels

exhibit a progressive, diurnal decline throughout the day, reaching a nadir in the late afternoon.

Environmental and occupational stressors such as rotating shift work schedules, chronic sleep fragmentation, and nighttime light pollution disrupt the transcriptional loops of these core clock genes. This molecular desynchronization blunts the morning testosterone surge, downregulates critical steroidogenic genes like *Star* and *Cyp11a1*, and correlates with systemic homeostatic alterations, including endothelial nitric oxide (NO/cGMP) pathway degradation and altered erectile function. Chronotherapeutic protocols indicate that exogenous androgen administration can be synchronized with this natural biological window. Delivering low-dose micro-injections during the morning hours aligns the exogenous testosterone with the endogenous surge schedule. This synchronization ensures that target peripheral tissues receive the androgen payload when receptor sensitivities are active. This alignment modulates the resolution of hypogonadal symptoms, alters metabolic biomarkers, stabilizes psychological mood, and avoids the systemic stress associated with non-circadian hormonal spikes.

4. Pharmacokinetic Hemodynamics of Closed-Loop Micro-Dosing

Transitioning from traditional fluid boluses to an automated, closed-loop subcutaneous micro-dosing protocol alters androgen safety profiles and hemodynamic management. The primary physiological mechanism driving testosterone-induced secondary erythrocytosis is the unphysiological serum peak generated by bolus injections. These rapid hormonal spikes stimulate renal erythropoietin (EPO) gene expression and suppress hepatic hepcidin transcription. The resulting decrease in hepcidin elevates dietary iron absorption and bone marrow erythropoiesis, driving patient hematocrit (HCT) levels beyond the clinical safety threshold of 54%. By continuously sampling blood hormone levels and utilizing automated microfluidic drives to deliver precise micro-doses scaled down to a 0.01 mL precision threshold, a closed-loop system modifies the serum concentration curve. Maintaining a steady-state within the mid-normal physiological range (450–600 ng/dL) keeps the signaling to the bone marrow uniform. This stabilization limits the rapid surges in EPO production that lead to

secondary polycythemia, thereby mitigating the unphysiological variations in blood hyperviscosity and elevated hematocrit that traditionally trigger strict criteria for clinical trial discontinuation, even though the direct translation of isolated TRT-induced erythrocytosis to active thromboembolic events remains a subject of ongoing clinical debate.

This pharmacokinetic consistency aligns with recent regulatory revisions. Following a clinical review demonstrating that approved testosterone formulations do not elevate the incidence of myocardial infarction or stroke relative to a placebo, the FDA updated its safety labeling on February 28, 2025, removing the primary cardiovascular warnings while introducing a specific mandate regarding treatment-induced blood pressure elevations. Traditional large-volume intramuscular boluses introduce a distinct risk profile for fluid retention and peripheral edema. Consequently, utilizing a microfluidic delivery system with a 0.01 mL volume threshold is designed to reduce sudden fluid shifts, thereby mitigating the physiological drivers of peripheral edema and therapy-induced blood pressure spikes.

5. Proactive Oncological Surveillance and PSA Velocity Analytics

Exogenous androgen therapy is strictly contraindicated in men with active or suspected prostate cancer or male breast cancer. According to the saturation theory of prostatic tissue, cellular proliferation within the prostate gland is sensitive to changes in serum androgen concentrations primarily at castrate or sub-physiological levels. Once circulating androgens reach normal physiological levels, the local androgen receptors achieve structural saturation, rendering the tissue largely insensitive to further concentration increases. Consequently, while exogenous testosterone administration does not initiate the *de novo* genetic formation of prostate cancer, it can accelerate the development and proliferation of pre-existing, occult, or hormone-dependent malignancies.

Traditional endocrine guidelines mandate standard Prostate-Specific Antigen (PSA) blood screenings at 3 to 6-month intervals. Under these trailing diagnostic protocols, an

absolute PSA velocity increase of greater than 1 ng/mL within the initial 6 months of therapy serves as an indicator of malignancy, requiring immediate cessation of treatment to investigate underlying prostate cancer. Integrating automated, continuous daily or monthly molecular tracking of PSA levels directly alongside real-time testosterone surveillance provides an active monitoring protocol. By charting an operator's real-time baseline PSA velocity, a closed-loop diagnostic framework can identify anomalous antigen spikes within days rather than months. If an accelerated or abnormal velocity curve is detected, the system can automatically initiate a safety shutdown before an occult tumor is driven into advanced development, providing a screening mechanism for patients with hidden hormone-dependent conditions.

6. Operational Characterization in Austere Environments

In remote or high-risk operational environments, such as active combat zones or prolonged field military deployments, sustained physical and psychological stress alters the human endocrine system. Chronic operational sleep fragmentation, physical exertion, and combat-induced stress disrupt the central SCN clock, triggering secondary hypogonadism. This endocrine alteration reduces fat-free muscle mass, affects bone mineral density, alters cognitive tracking, and reduces overall stress recovery capacity. Deploying traditional intramuscular bolus therapy within these environments introduces operational variables and specific risks. Administering a manual IM injection requires a secure field, large-gauge needles, and the manual handling of thick, oil-based solutions conditions that are difficult to maintain during active field operations. Furthermore, the physical exertion of combat alters the physical absorption of an intramuscular muscle depot, increasing the risk of acute polycythemia and dehydration-induced clotting events. The risk of an unpredictable POME episode also introduces an operational liability; an acute coughing fit caused by oil entering the venous system directly compromises noise discipline and operational security in hostile territory.

Transitioning to an automated, subcutaneous closed-loop microfluidic system modifies these operational risks. The compact format utilizes micro-cannulas, eliminating field contamination risks and needle-related trauma. By providing a continuous stream of

micro-doses, the system ensures physical endurance and cognitive tracking independent of erratic operational schedules. It isolates the operator from the physiological drops of hormone troughs and the vascular risks of hormone peaks, offering an autonomous mechanism for human performance preservation under duress (see **Table 6.1**).

Table 6.1. Tactical and Operational Modality Comparison in Austere Environments.

Operational Stress Vector	Traditional Intramuscular (IM) Bolus Protocol	Automated Subcutaneous (SC) Closed-Loop Protocol
Field Logistics & Deployment	Requires large-gauge manual needles, vials, and a sterile field setup, introducing a risk of deep tissue contamination in the field.	Utilizes a compact, self-contained, automated micro-cannula deployment that limits environmental contamination vectors.
Pharmacokinetic Stability	Large, infrequent dosing blocks cause hormonal volatility and symptomatic drops under chronic operational stress.	Provides continuous, steady-state hormone release to maintain baseline physiological reserves.
Hemodynamic Adaptation	Intense combat physical exertion triggers volatile, rapid muscle absorption, compounding baseline	Hypodermal tissue absorption relies strictly on steady, intrinsic lymphatic drainage, remaining independent of muscle exertion.

	hyperviscosity and clotting risks.	
Operational Security	Carries a 1.9% clinical risk of acute Pulmonary Oil Microembolism (POME), causing coughing fits that affect noise discipline.	Eliminates POME risk due to the minimal macro-vasculature present within the subcutaneous layer.
Performance Maintenance	Subjects the operator to hormonal nadirs, causing fatigue, altered cognitive tracking, and impaired recovery profiles.	Preserves critical cognitive tracking capabilities, physical strength, and restorative sleep architecture under duress.

7. Comparative Performance and Adverse Profile Matrix

The structural, physiological, and metabolic variations between traditional manual intramuscular bolus therapy and the automated, closed-loop subcutaneous micro-dosing paradigm are systematically evaluated across core clinical complications and operational performance categories (see **Table 6.2**).

Table 6.2. Comparative Endocrine Complications and Systemic Adverse Profile Matrix.

Complication / Diagnostic Category	Manual Intramuscular (IM) Bolus Protocol	Automated Closed-Loop Subcutaneous (SC) Micro-Dosing

Pharmacokinetic Profile	Volatile, high peak-to-trough fluctuations over a 14-day cycle.	Smooth, steady-state homeostatic maintenance within the target physiological range.
Erythrocytosis Risk	Elevated (>20% incidence); sharp spikes trigger excessive erythropoietin signaling, driving HCT > 54%.	Controlled; steady-state delivery limits rapid EPO surges and manages blood viscosity.
Pulmonary Oil Microembolism (POME)	Documented 1.9% risk of acute coughing fits and respiratory distress via accidental venous introduction.	Eliminated; hypodermal adipose tissue contains minimal large macro-vasculature.
Oncological Surveillance	Reactive detection via standard 3-to-6 month blood draws.	Continuous baseline tracking via automated analysis of daily/monthly PSA velocity trends.
Cardiovascular / Fluid Safety	High bolus volumes can induce fluid retention, localized edema, and blood pressure spikes.	Micro-doses (0.01 mL) maintain fluid balance and minimize blood pressure strain.

Chronobiological Alignment	Independent of circadian rhythms; overrides natural diurnal cycles.	Synchronized; automated to target the standard morning physiological surge.
Tactical / Field Viability	Low operational viability; requires a sterile field, manual needles, and carries a noise risk from POME.	Structured for field resilience, autonomy, and physical performance preservation under duress.
Long-Term Patient Adherence	Poor (95% attrition rate at 12 months) associated with injection pain and tissue trauma.	High compliance matching automated micro-dosing delivery features.

Disclosures and Conflicts of Interest

The authors declare a financial conflict of interest. López Díaz is a founder/shareholder of karē, a biotechnology entity developing closed-loop subcutaneous delivery systems. The theoretical and physiological mechanisms reviewed in this manuscript represent objective biomedical analysis and are independent of proprietary commercial validation.

Funding Statement

This research did not receive specific grants from funding agencies in the public, commercial, or not-for-profit sectors. Structural support was provided internally by the institutional research budget of Karē Corp.

8. References

- Demir, E., & Akpınar, E. (2026). Testosterone Replacement Therapy: Indications, Application Protocols, and Side Effect Profile. *Recent Trends in Pharmacology*, DOI: 10.62425/rtpharma.1829150.
- Figueiredo, M. G., Gagliano-Jucá, T., & Basaria, S. (2022). Testosterone Therapy With Subcutaneous Injections: A Safe, Practical, and Reasonable Option. *The Journal of Clinical Endocrinology & Metabolism*, 107(3), 614-626.
- Ning, G., Li, B. N., Wu, H., Shi, R. B., Peng, A. J., Wang, H. Y., & Zhou, X. (2025). Regulation of testosterone synthesis by circadian clock genes and its research progress in male diseases. *Asian Journal of Andrology*, 27, 564-573.
- Osterberg, E. C., Bernie, A. M., & Ramasamy, R. (2014). Risks of testosterone replacement therapy in men. *Indian Journal of Urology*, 30(1), 2-7.
- Wittert, G. (2014). The relationship between sleep disorders and testosterone in men. *Asian Journal of Andrology*, 16(2), 262-265.